Get the Stockscreener App
8.70
0.11%
-0.01
After Hours:
8.70
Satellos Bioscience Inc stock is traded at $8.70, with a volume of 37,197.
It is down -0.11% in the last 24 hours and down -7.45% over the past month.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$8.71
Open:
$8.775
24h Volume:
37,197
Relative Volume:
0.72
Market Cap:
$184.58M
Revenue:
-
Net Income/Loss:
$-28.50M
P/E Ratio:
-4.7992
EPS:
-1.8128
Net Cash Flow:
$-25.87M
1W Performance:
-6.65%
1M Performance:
-7.45%
6M Performance:
+22.19%
1Y Performance:
+0.00%
1-Day Range:
$8.535
$8.86
1-Week Range:
$8.36
$9.47
52-Week Range:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
8.70 | 184.58M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Initiated | Leerink Partners | Outperform |
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - Investing News Network
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application - marketscreener.com
Satellos Bioscience Inc. - Baystreet.ca
Stocks in play: Satellos Bioscience Inc. - ca.finance.yahoo.com
Satellos Receives FDA Clearance to Study Forazapadin in FSHD - Yahoo Finance
Satellos stock jumps after FDA clears FSHD trial for forazapadin - Yahoo Finance
Satellos stock jumps after FDA clears FSHD trial for forazapadin By Investing.com - Investing.com Australia
Satellos receives FDA clearance for FSHD drug trial - Investing.com
Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding - TipRanks
Satellos Bioscience Inc. (MSLE) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA clears a Satellos (MSLE) drug study for a disease affecting an estimated 800,000 people worldwide. - Stock Titan
Satellos receives FDA clearance for FSHD drug trial By Investing.com - Investing.com Canada
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - Caledon Enterprise
Satellos Bioscience Inc.(NasdaqGM: MSLE) added to S&P Global BMI Index - marketscreener.com
Satellos at H.C. Wainwright conference: DMD drug aims wider - Investing.com
Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress - TipRanks
Satellos Bioscience Announces Four Poster Presentations at the 2026 World Muscle Society Congress - Quiver Quantitative
Cash runway through 2027 backs Satellos (MSLE) muscle disease trials - Stock Titan
WHY Draganfly (CN:DPRO), Eco (Atlantic) Oil & Gas (TSXV:EOG), Mayfair Gold (TSXV:MFG), Satellos Bioscience (TSX:MSCL) and Foraco International SA (TSX:FAR) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
Satellos Bioscience Stock Faces Downside Pressure as Clinical Expectations Rise: Is Correction Risk Building? - kalkine.ca
Satellos Bioscience Stock Drops 5.24%: Is TSX:MSCL Facing a Sentiment-Driven Correction Ahead of Key Clinical Catalysts? - kalkine.ca
What's Going On With Satellos Bioscience Inc. Stock Friday? - Wealth Awesome
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
Satellos Bioscience (TSX:MSCL) Gains Momentum as Clinical Progress and Regenerative Medicine Potential Drive Investor Optimism - kalkine.ca
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 - Investing News Network
Satellos at Cantor healthcare conference: pipeline nears key data - Investing.com
Satellos at Cantor healthcare conference: pipeline nears key data By Investing.com - Investing.com UK
MSCL: Phase II trials of forazapadin show early promise in muscle regeneration, with pivotal data expected soon - TradingView
Satellos Bioscience is facing clinical execution risks—can it regain investor confidence and turn sentiment around? - kalkine.ca
Satellos assigns INN forazapadin to DMD drug candidate By Investing.com - Investing.com Canada
Satellos assigns INN forazapadin to DMD drug candidate - Investing.com
Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance - TipRanks
New muscle disease pill from Satellos Bioscience (MSLE) nears key Duchenne trial readout - Stock Titan
A muscle disease treatment candidate gets a new global name: forazapadin - Stock Titan
Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Did Satellos Bioscience (TSX:MSCL) Surge 7.43% on 31 August 2026? - kalkine.ca
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences - TipRanks
Satellos to Participate in Upcoming Investor Conferences - The Manila Times
Satellos cash runway through 2027, Phase 2 DMD | MSLE SEC FilingForm 6-K - Stock Titan
Satellos Bioscience (TSX:MSCL) Rises 7.43% as Duchenne Clinical Progress and Upcoming Data Catalysts Lift Investor Optimism - kalkine.ca
Satellos Bioscience Stock Falls 7.42% as Clinical-Stage Risk and Development Uncertainty Pressure Sentiment - kalkine.ca
Satellos Bioscience Inc. (TSX:MSCL) Falls 7.42% as Biotech Volatility and Clinical Development Risks Pressure Investor Confidence - kalkine.ca
LifeSci Capital Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Satellos Bioscience (MSLE) Slides Nearly 10% in High-Volume Biotech SelloffCalendar Spread Trade - vinanet.vn
Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE - marketbeat.com
Could Satellos Bioscience (TSX:MSCL) Redefine Muscle Regeneration? - Kalkine Media
LifeSci Capital Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $22 - Moomoo
LifeSci Capital Initiates Satellos Bioscience at Outperform - Yahoo Finance
Satellos Bioscience Stock Under Pressure as Biotech Volatility Raises Correction Risk - kalkine.ca
Satellos (MSLE) Stock: Ends Higher by 0.59% at $10.15 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest ReadingMonthly Profile - vinanet.vn
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):